Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

cg or 15mcg of sufentanil. Doses were delivered sublingually as needed to treat pain with a 20-minute minimum re-dosing interval and patients were allowed to drop out of the study at any time. Positive results were also obtained for the primary endpoint following treatment with the 15mcg dose compared to placebo using two alternate methods for imputing missing data from drop-outs: baseline observation carried forward (BOCF), p = 0.007, and last observation carried forward (LOCF), p = 0.018. Importantly, there were no events of clinically significant respiratory depression for any dosing group. Based on these positive results, AcelRx intends to further advance clinical development of ARX-01 in 2009.

"We are pleased by the wonderful clinical results of our Phase 2 post-operative acute pain study," said Thomas A. Schreck, chairman and chief executive officer of AcelRx Pharmaceuticals. "This is the culmination of a great deal of hard work by a team of efficient, dedicated people over the last two years, and is therefore very gratifying indeed. This trial has the benefit of validating Sublingual Sufentanil NanoTabs as a robust product candidate for its initial in-hospital acute pain indication, as well as providing the foundation of safety and efficacy for the other programs in our pipeline."

About ARX-01 Sublingual Sufentanil NanoTabs

Sufentanil is currently approved as an intravenous (IV) anesthetic and is also indicated for epidural administration during labor and delivery. Due to their small size, ARX-01 Sublingual Sufentanil NanoTabs are convenient, well-tolerated, have high bioavailability and provide lower peak plasma levels compared to IV administration.

About the ARX-01 Oral Patient-Controlled Analgesia System

The ARX-01 Oral Patient-Controlled Analgesia (PCA) system is based on a proprietary pre-programmed, hand-held dispenser being developed by AcelRx. The AcelRx d
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... the Global Supply Chain of the biotech industry. ... SCM Innovation Awards, brought to you by the ... global organization of supply chain management professionals for ... given to stakeholders of the Biotech industry – ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... leading,supplier of virtual reality based training applications within the ... of the Board and,Goran Malmberg as President and CEO ... and brings with him a vast,array of experience in ... of several Swiss private and charitable foundations. Mr.,Ruscoe is ...
... Ltd. (ASX: PXL),CEO Dr Jenny Harry has been ... in Washington DC at the Partnering for Global ... Foundation and organised by Bio,Ventures in Global Health, ... http://pgh.bio.org/opencms/PGH/2008/program/program.jsp , The Forum follows a report ...
... researchers at the National Institute of Standards and ... in solution as they dart around in three ... plans to patent, will lead to a better ... and, ultimately, process control techniques to optimize the ...
Cached Biology Technology:Mentice AB Announces Leadership Changes Within Its Worldwide Operations 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 3All done with mirrors: NIST microscope tracks nanoparticles in 3-D 2
(Date:7/25/2014)... at the University of Houston, has written a ... development., "Introduction to Tissue Engineering: Applications and Challenges" ... field of artificial organ development. Metin Akay, founding ... served as a series editor on the book., ... books on the subject of growing artificial organs ...
(Date:7/25/2014)... research at the University of Adelaide has opened the way ... to powdery mildew. , In Australia, annual barley production is ... Powdery mildew is one of the most important diseases of ... have discovered the composition of special growths on the cell ... fungus into the leaf. , The research, by the ARC ...
(Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... FINDINGS: Short pieces of RNA, called microRNAs, control protein ... as messenger RNA or mRNA) to be disabled by ... Researchers have known that mammalian microRNAs control protein production ... wondered how much additional effects microRNAs impart by jamming ...
... OTO EXPO of the American Academy of Otolaryngology Head ... nose, and throat doctors in the world, will convene September ... 305 scientific research sessions, 594 posters, and several hundred instruction ... opportunity for journalists from around the world to cover breaking ...
... the cause of some of the most repugnant smells on ... forms actually has a sense of smell of its own. ... for the first time that bacteria have a molecular "nose" ... ammonia. Published today in Biotechnology Journal , their study ...
Cached Biology News:RNA snippets control protein production by disabling mRNAs 2RNA snippets control protein production by disabling mRNAs 3Bacteria breakthrough is heaven scent 2
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... Biochain's plant total protein western ... rapidly screening tissue specific protein ... placenta total protein is included ... interblot control for comparison between ...
...
Biology Products: